BGOG-ov-50

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)

Sponsor: Novocure

Participating sites:

  • CHU UCL Namur, site Sainte Elisabeth, Namur
  • UZ Gent, Gent
  • UZ Leuven, Leuven
  • CHU Ambroise Paré, Mons
  • AZ Maria Middelares, Gent
  • CHU Dinant Godinne, Yvoir
  • Grand Hôpital de Charleroi, Charleroi
  • Imelda ziekenhuis, Bonheiden
  • CHU UCL St-Luc, Bruxelles